SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-1.1
Date Filed: 2025-08-27
Accession Number: 0001213900-25-081175
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025081175/ea025480001ex1-1_synergy.htm

Chunk 1 of 27
Word Count: 1370
Character Count: 8914

Document Content:

Communications. Except as approved in writing by the Representative, the Company (i) has not alone engaged in any Testing-the-Waters Communication and (ii) has not authorized anyone to engage in Testing-the-Waters Communications. The Company has not distributed any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act (“Written Testing-the-Waters Communications”), other than those previously provided to the Representative and listed on Schedule IV hereto. “Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act. Each Written Testing-the-Waters Communication, did not, as of the Applicable Time, and at all times through the completion of the public offer and sale of Shares will not, include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. (vi) Accurate Disclosure.

(A) The Company has
provided a copy to the Representative of each Issuer Free Writing Prospectus (as defined below) used in the sale of Shares. The Company
has filed all Issuer Free Writing Prospectuses required to be so filed with the Commission, and no order preventing or suspending the
effectiveness or use of any Issuer Free Writing Prospectus is in effect and no proceedings for such purpose have been instituted or are
pending, or, to the knowledge of the Company, are contemplated or threatened by the Commission. When taken together with the rest of the
Time of Sale Disclosure Package or the Final Prospectus, no Issuer Free Writing Prospectus, as of its issue date and at all subsequent
times though the completion of the public offer and sale of Shares does or will include (1) any untrue statement of a material fact or
omission to state any material fact necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading, or (2) information that conflicted, conflicts or will conflict with the information contained in the Registration
Statement or the Final Prospectus. The representations and warranties set forth in the immediately preceding sentence shall not apply
to statements in or omissions from the Time of Sale Disclosure Package, the Final Prospectus or any Issuer Free Writing Prospectus in
reliance upon, and in conformity with, written information furnished to the Company by the Representative specifically for use in the
preparation thereof, which written information is described in Section 7(f). As used in this paragraph and elsewhere in this Agreement:

(1) “Time of
Sale Disclosure Package” means the Prospectus most recently filed with the Commission before the date of this Agreement, each
Issuer Free Writing Prospectus, and the description of the transaction provided by the Representative included on Schedule II.

(2) “Issuer
Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 under the Securities
Act, relating to the Securities that (A) is required to be filed with the Commission by the Company, or (B) is exempt from filing pursuant
to Rule 433(d)(5)(i) or (d)(8) under the Securities Act, in each case in the form filed or required to be filed with the Commission or,
if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act.

(B) Each Issuer Free
Writing Prospectus listed on Schedule III satisfied, as of its issue date and at all subsequent times through the Prospectus Delivery
Period, all other conditions as may be applicable to its use as set forth in Rules 164 and 433 under the Securities Act, including any
legend, record-keeping or other requirements.

(vii) Financial
Statements. The financial statements, including the notes thereto and supporting schedules (if any) included in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus, fairly present in all material respects the financial position, the results
of operations, changes in stockholders’ equity and cash flows of the Company at the dates and for the periods to which they apply.
Such financial statements have been prepared in conformity with generally accepted accounting principles generally accepted in the United
States of America (“GAAP”), consistently applied throughout the periods involved; provided that unaudited interim financial
statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain all of the
notes required by GAAP and the supporting schedules, if any, included in the Registration Statement present fairly the information required
to be stated therein. Except as included therein, no historical or pro forma financial statements are required to be included in the Registration
Statement, the Time of Sale Disclosure Package or the Final Prospectus under the Securities Act or the rules and regulations thereunder.
All disclosures contained in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus regarding “non-GAAP
financial measures” (as such term is defined by the rules and regulations of the Commission), if any, comply in all material respects
with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration
Statement, the Time of Sale Disclosure Package and the Final Prospectus discloses all material off-balance sheet transactions, arrangements,
obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that
may have a material current or future effect on the Company’s financial condition, changes in financial condition, results of operations,
liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration
Statement, the Time of Sale Disclosure Package and the Final Prospectus, (a) neither the Company nor any of its direct and indirect subsidiaries,
including each entity disclosed or described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus
as being a subsidiary of the Company (each, a “Subsidiary” and, collectively, the “Subsidiaries”),
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the
ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect
to its capital stock, (c) there has not been any change in the capital stock of the Company or any of its Subsidiaries, other than in
the course of business or pursuant to any grants under any stock compensation plan, and (d) there has not been any material adverse change,
or any development that could reasonably be expected to result in a material adverse change, in the business, prospects, properties, operations,
condition (financial or otherwise) or results of operations of the Company and its Subsidiaries, taken as a whole, or in its ability to
perform its obligations under this Agreement (any such change, a “Material Adverse Change”), in the Company’s
long-term or short-term debt.

(viii) Independent
Accountants. RBSM LLP (the “Auditor”), whose reports are filed with the Commission as part of the Registration
Statement, the Time of Sale Disclosure Package and the Final Prospectus, is an independent registered public accounting firm as required
by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board (the “PCAOB”),
including the rules and regulations promulgated by such entity. To the Company’s knowledge, after reasonable inquiry, the Auditor
is currently registered and in good standing with the PCAOB and the PCAOB has not made any determination with respect to the Auditor under
the Holding Foreign Companies Accountable Act. The Auditor has not, during the periods covered by the financial statements included in
the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, provided to the Company any non-audit services,
as such term is used in Section 10A(g) of the Exchange Act. To the Company’s knowledge, no person who has been suspended or barred
from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated
by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or
other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Disclosure Package or the Final
Prospectus.